BEIJING, May 27 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) (“Lotus” or the “Company”), a pharmaceutical company in the People’s Republic of China ("PRC"), today announced that it will conduct a conference call at 10:00 a.m. Eastern Time on Tuesday, May 27, 2008 to discuss the first quarter 2008 results.
Joining Mr. Zhongyi Liu, Chairman and Chief Executive Officer of Lotus Pharmaceuticals, will be Mr. Adam Wasserman, Chief Financial Officer.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time:
888-481-7939. International callers should dial 617-847-8707, Conference Passcode: 45954238.
If you are unable to participate in the call at this time, a replay will be available for seven days starting on May 27, at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, and enter the passcode of 82020022.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. (“Lotus”) controls and operates Liangfang Pharmaceutical, Ltd. (“Liangfang”) and Enze Jiashi Pharmaceutical, Ltd. (“En ze”), two Chinese pharmaceutical companies located in Beijing (together “Lotus East”). Lotus East is a comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. The Company possesses some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Lotus East, and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines through 10 retail pharmacy location through Beijing. For more information, visit http://www.LotusEast.com .
Safe Harbor Statement
Certain statements set forth in this press release constitute
"forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company’s actual results and financial position to differ materially from those included within the forward-looking statements. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Mr. Adam Wasserman, CFO
Phone: +1-877-801-0344
Email: info@LotusEast.com
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Website: http://www.ccgelite.com
